Combination of interferon and ribavirin in chronic hepatitis C: Re-treatment of nonresponders to interferon

Hepatology

Volumn 33, Issue 3, 2001, Pages 704-707

  Di Bisceglie, Adrian M ^a   Thompson, Judy ^a   Smith Wilkaitis, Nancy ^a   Brunt, Elizabeth M ^b   Bacon, Bruce R ^a  

^a Div of Gastroenterol and Hepatol   (United States)

^b SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA2A INTERFERON; ALPHA2B INTERFERON; INTERFERON; RIBAVIRIN;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CANCER GRADING; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG MIXTURE; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0035120818     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2001.22346     Document Type: Article

References (20)

1. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
2. Randomised trial of interferon alfa-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alfa-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
3. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C
4. Is an "A la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first liner treatment in patients with chronic hepatitis C?
5. Classification of chronic viral hepatitis: A need for reassessment
6. A comparison of reverse transcription-polymerase chain reaction and branched-chain DNA assays for hepatitis C virus RNA in patients receiving interferon treatment
7. Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay
8. EASL international Consensus Conference on hepatitis C
9. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration
10. Therapy of hepatitis C: Re-treatment with alpha interferon
11. Re-treatment of chronic hepatitis C with consensus interferon
12. The pattern of response to interferon alpha (a-IFN) predicts sustained response to a 6-month α-IFN and ribavirin retreatment for chronic hepatitis C
13. A randomized trial of ribavirin and interferon-α vs interferon-α alone in patients with chronic hepatitis C who were non-responders to a previous treatment
14. Interferon-α-2b and ribavirin in combination for chronic hepatitis C patients not responding to interferon-a alone: An Italian multicenter, randomized, controlled, clinical study
15. Racial differences in responses to therapy with interferon in chronic hepatitis C
16. Correlation of biochemical response to interferon alfa with histological improvement in hepatitis C: A meta-analysis of diagnostic test characteristics
17. Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: A multi-center, prospective, randomized, controlled trial
18. Interferon and ursodeoxycholic acid combined therapy in the treatment of chronic viral C hepatitis: Results from a controlled randomized trial in 80 patients
19. A randomised, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia
20. Therapy of hepatitis C: Patients with normal aminotransferase levels